Draig Therapeutics, a UK-based biotechnology firm, has successfully secured $65 million in a Series B financing round to advance its innovative pipeline of psychiatric drugs. This new capital injection will primarily support the clinical development of its lead candidate, DT-101, for the treatment of major depressive disorder. The funding underscores growing investor confidence in the company's novel approach to rebalancing brain chemistry and addressing significant unmet needs in mental health.
Strategic Investment to Fuel Clinical Progress
The financing was led by new investor Deep Track Capital and saw participation from Janus Henderson Investors, Marshall Wace, British Business Bank, and Jefferson Life Sciences. This round follows a substantial $140 million Series A, providing Draig with a robust financial foundation to accelerate its programs. According to CEO Ivana Magovčević-Liebisch, the funds will expedite the progress of DT-101 and the company's broader research and development efforts.
A Novel Approach to Treating Depression
Draig's lead asset, DT-101, is an oral positive allosteric modulator designed to target AMPA receptors, which are crucial for transmitting excitatory signals in the brain. Instead of directly activating the receptor, the molecule amplifies its response to the neurotransmitter glutamate. This mechanism aims to rebalance brain circuits involved in depression while potentially avoiding safety issues associated with less selective treatments.
The company has already reported positive safety, tolerability, and target engagement data from a Phase 1 study involving 60 healthy volunteers. DT-101 is now being evaluated in two pivotal Phase 2 trials: a global study as a standalone therapy and a U.S. study as an add-on to existing antidepressants. Initial clinical readouts from both trials are expected in 2027, which will provide the first major test of the drug's efficacy.
Expanding the Neuropsychiatric Pipeline
Beyond its lead candidate, Draig is developing a broader portfolio to address various psychiatric conditions. The company is advancing two other programs, DT-201 and DT-301, which are highly selective modulators of GABA-A receptors that regulate inhibitory signaling. These assets are slated to move toward clinical evaluation in 2026, though their specific initial indications have not yet been disclosed.
Navigating a Challenging but Promising Field
Draig is entering a notoriously difficult area of drug development, where clinical trials often face challenges such as large placebo responses. The company faces competition from others exploring AMPA modulation, like Neurocrine Biosciences, as well as from emerging psychedelic therapies from firms such as Compass Pathways. Success in this high-risk, high-reward field could significantly alter the treatment landscape for millions of patients suffering from debilitating mental health disorders.
This $65 million financing round marks a critical milestone for Draig Therapeutics, equipping it with the resources to navigate the demanding path of neuropsychiatric drug development. The investment validates the company's scientific platform, which originated from research at Cardiff University, and positions it to deliver key clinical data in the coming years. The upcoming Phase 2 results for DT-101 will be closely watched as a potential breakthrough for patients with major depressive disorder.